SCHEMBL17137125

SCHEMBL17137125

C[C@]1(F)C[C@@H](CO)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 8/20 0.38
PRKCA P17252 5/20 0.35
CREBBP Q92793 1/20 0.34
PYGM P11217 1/20 0.33
APLNR P35414 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17136876 1.00 IRAK4 (0.38) IRAK4PRKCACREBBPPYGMAPLNR
SCHEMBL21338570 1.00 IRAK4 (0.38) IRAK4PRKCACREBBPPYGMAPLNR
SCHEMBL209721 0.80 CREBBP (0.36) IRAK4PRKCACREBBPPYGMAPLNR
SCHEMBL15549632 0.80 CREBBP (0.36) IRAK4PRKCACREBBPPYGMAPLNR
SCHEMBL5213404 0.80 PRKCA (0.37) IRAK4PRKCACREBBPPYGM
SCHEMBL5213410 0.80 PRKCA (0.37) IRAK4PRKCACREBBPPYGM
SCHEMBL209722 0.80 CREBBP (0.36) IRAK4PRKCACREBBPPYGMAPLNR
SCHEMBL1387675 0.80 PRKCA (0.37) IRAK4PRKCACREBBPPYGM
SCHEMBL17137108 0.79 IRAK4 (0.39) IRAK4PRKCACREBBPPYGM
SCHEMBL17137036 0.78 IRAK4 (0.40) IRAK4PRKCACREBBPPYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2025-01-21 US disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 US disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 US disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 US disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 US disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 US disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 US disclosed
EP-3536685-B1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER (US) 2022-02-16 EP disclosed
EP-3536685-B1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER (US) 2022-02-16 EP disclosed
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2020-12-03 US disclosed
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2016-12-01 US disclosed
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2016-12-01 US disclosed
US-9458168-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2016-10-04 US disclosed
US-9458168-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2016-10-04 US disclosed
US-9458168-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2016-10-04 US disclosed
WO-2015150995-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER INC. (US) 2015-10-08 WO disclosed
WO-2015150995-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER INC. (US) 2015-10-08 WO disclosed
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2015-10-08 US disclosed
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2015-10-08 US disclosed
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 IRAK4 4619/4885PRKCA 4603/4885CREBBP 3531/4885
US-20150284405-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 IRAK4 4619/4885PRKCA 4603/4885CREBBP 3531/4885
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 IRAK4 4619/4885PRKCA 4603/4885CREBBP 3531/4885
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds TTR, TYR, ABL1 IRAK4 1318/4885PRKCA 4601/4885CREBBP 1633/4885
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds TTR, TYR, ABL1 IRAK4 1318/4885PRKCA 4601/4885CREBBP 1633/4885
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 IRAK4 4619/4885PRKCA 4603/4885CREBBP 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.